CRS 207

Drug Profile

CRS 207

Alternative Names: ANZ-207; Cancer vaccine - Aduro BioTech; CRS-207; Listeria monocytogenes-expressing mesothelin - Aduro Biotech

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cerus Corporation; Chugai Pharmaceutical; Johns Hopkins University
  • Developer Aduro BioTech; Merck AG
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Megakaryocyte potentiating factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Fallopian tube cancer; Gastric cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 23 Jan 2018 Sidney Kimmel Comprehensive Cancer Center initiates enrolment in a phase II trial for Pancreatic cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (NCT03006302)
  • 18 Dec 2017 Discontinued - Phase-I/II for Peritoneal cancer (Combination therapy, Second-line therapy or greater) in USA (Parenteral)
  • 18 Dec 2017 Discontinued - Phase-II for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top